The Asia Generic Pharmaceuticals Forecast Report Includes BMI's independent 5-year generics industry forecasts for 14 Asian markets:
Australia, China, Hong Kong, India, Indonesia, Japan, Malaysia, Pakistan, Philippines, Singapore, South Korea, Taiwan, Thailand and Vietnam
Business Monitor International's Asia Generic Pharmaceuticals Forecast Report provides industry professionals, key company personnel, market investors, and corporate and financial services analysts with comparative 5-year forecasts and competitive intelligence on the generics industry and key generics players across 14 Asian markets (see above).
The Report has just been researched at source, and features country-by-country generics data and 5-year forecasts to end-2009, plus newly researched competitive intelligence and SWOT analyses on leading generics companies active across 14 Asian markets
Companies covered in the Report include: Ranbaxy (India), Dr. Reddy's (India), Nicholas Piramal (India), Sawai Pharmaceutical (Japan), North China Pharmaceutical Corporation (China), Mayne Group (Australia), Dong-A (Korea), DaeWoong (Korea), Haw Par Corporation (Singapore), Yung Shin Pharmaceutical (Taiwan), Siam Pharmaceutical (Thailand), Vida Laboratories (Hong Kong), Pharmaniaga (Malaysia), Vinapharm (Vietnam) Kalbe Farma (Indonesia), Unilab (Philippines)
The Asia Generic Pharmaceuticals Forecast Report projects future trends in key markets:
Japan will be Asia's biggest branded generics market by the end of the decade, as the government continues to cut drug costs and make hospitals and consumers more price aware
Australia will remain an attractive generics market, despite new access barriers created by the US free trade agreement and reform of the PBS
China’s generics market will continue to expand strongly, but success will depend on brand strength – as the population remains reliant on basic drugs
India's patent law should clarify distinctions between so-called 'innovative' drugs and generics, with gradual insurance sector liberalisation driving demand
Margins on generic drugs will look negative over the forecast period in Taiwan, as the public reimbursement system enters a period of crisis
The strength of Korea's generic manufacturers will continue, but quality generics makers have little to fear from patent and pricing reform
Exposure to international currency effects will increase import dependency for manufacturers in emerging Asian markets including Indonesia and the Philippines
KEY BENEFITS of the Asia Generic Pharmaceuticals Forecast Report
Benchmark consensus views against BMI's independent 5-year generics forecasts: All our pharmaceuticals and healthcare forecasts derive from a 50-50% interaction between our econometric model of the world, and our pharmaceuticals industry analysts. In particular, BMI's pharmaceuticals forecasts are based on co-relationships between key macroeconomic and socio-demographic drivers, and drug market performance and outlook
Exploit competitive intelligence on leading companies: BMI's company SWOT analyses and profiles are the result of latest-available research, and give insights into the strategies of competitor companies operating in Asia
Target new business opportunities:
For more information, Please visit :
http://www.bharatbook.com/
